Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Leading medical devices maker C.R. Bard (BCR - Analyst Report) has scooped up Minnesota-based Lutonix, Inc. for roughly $225 million. The deal also calls for an additional milestone payment of $100 million, to be paid upon the U.S. premarket approval (“PMA”) of Lutonix’s drug-coated percutaneous transluminal angioplasty (“PTA”) balloon.

Lutonix is currently conducting an FDA-approved investigational device exemption (“IDE”) study (“LEVANT 2”) using drug-coated balloons for treating peripheral arterial disease, a condition affecting roughly 8 to 12 million people in the U.S.

The trial is comparing Lutonix’s drug-coated balloon (dubbed Moxy) with standard balloon angioplasty. The multi-center pivotal study will enroll 476 patients with significant stenosis (narrowing of a blood vessel) in previously unstented superficial femoral artery or popliteal artery lesions (up to 150 mm in length) across 55 sites in the U.S. and Europe.

These patients will be monitored for five years, following which, a PMA application will be filled with the FDA after a year, which Lutonix currently expects to occur in 2014. The company has already received European CE Mark for its drug-coated balloon. C.R. Bard expects to commence selling the device in Europe in second-half 2012.

Drug-coated balloons are gaining attention recently as surgeons look for effective means to treat diseased arteries without having to leave a permanent implant. Similar to the drug-eluting stents (“DES”) used in the heart, the drug-coated balloon delivers a powerful restenosis (reoccurrence of stenosis)-fighting drug to the artery. However, unlike DES, it is removed from the body after use.

The worldwide peripheral vascular market for drug-coated balloons is forecast to hit roughly $1 billion annually over the next ten years. Currently, there are no approved drug-coated balloons available for use in the U.S.

The acquisition is a strategic fit for C.R. Bard, enabling it to expand into a large and lucrative market. The company, however, envisions the transaction to dilute its adjusted earnings per share for 2012 by roughly 25 cents.

C.R. Bard’s well-diversified end-markets and vast product portfolio insulate it from fluctuations in any single therapeutic category. The company’s resource depth and focused innovation are its major competitive advantages.

We expect new products to drive organic revenue growth and help C.R. Bard to meet its sales objective. However, heightened competition and pricing/procedure volume pressure remain areas of concern. C.R. Bard faces tough competition from larger players such as Boston Scientific (BSX - Analyst Report) and Johnson & Johnson (JNJ - Analyst Report). Our Neutral recommendation on the stock is in tandem with a short-term Zacks #3 Rank (Hold).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%